

BEST AVAILABLE COPY **COPY**

PTO/SB/21 (08-00)



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/810,310
Filing Date	March 14, 2001
First Named Inventor	Khleif, Samir N.
Group Art Unit	1644
Examiner Name	M. Dibrino
Attorney Docket Number	015280-415100US

Total Number of Pages in This Submission

1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449; References: AA-DC; Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Brian W. Poor	Reg. No. 32,928
Signature	<i>Brian W. Poor</i>	
Date	31 January 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

Jan 31, 2003

Typed or printed name	Jennifer M. Smolen
Signature	<i>J M Smolen</i>
Date	<i>Jan 31, 2003</i>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. on

Jan. 31, 2003
By: [Signature]



PATENT
Attorney Docket No. 015280-415100US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Samir Khleif *et al.*

Application No.: 09/810,310

Filed: March 14, 2001

For: METHODS AND COMPOSITIONS
FOR CO-STIMULATION OF
IMMUNOLOGICAL RESPONSES
TO PEPTIDE ANTIGENS

Examiner: M. Dibrino

Art Unit: 1644

**INFORMATION DISCLOSURE
STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants direct the Examiner's attention to the references below, also listed on the accompanying Form PTO-1449. A copy of each is also enclosed.

The following U.S. Patents are set forth below by issue date.

AA. U.S. Patent No. 4,599,230, issued on July 8, 1986 to Milich *et al.*

AB. U.S. Patent No. 4,599,231, issued on July 8, 1986 to Milich *et al.*

AC. U.S. Patent No. 5,861,310, issued on January 19, 1999 to Freeman *et al.*

AD. U.S. Patent No. 5,866,553, issued on February 2, 1999 to Donnelly *et al.*

AE. U.S. Patent No. 5,942,607, issued on August 24, 1999 to Freeman *et al.*

The following foreign patent publications are set forth by approximate publication date:

The following articles are set forth in alphabetical order:

AG. Acsadi *et al.*, "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," *Nature* 352:815-818 (1991)

AH. Aichele *et al.*, "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," *J. Exp. Med.* 171:1815-1820 (1990)

AI. Armitage *et al.*, "Molecular and biological characterization of a murine ligand for CD40," *Nature* 357:80-82 (1992)

AJ. Azuma *et al.*, "B70 antigen is a second ligand for CTLA-4 and CD28," *Nature* 366:76-79 (1993)

AK. Baskar *et al.*, "Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules," *Proc. Natl. Acad. Sci. USA* 90:5687-5690 (1993)

AL. Bleijs *et al.*, "Co-stimulation of T cells results in distinct IL-10 and TNF- α cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3," *Eur. J. Immunol.* 29:2248-2258 (1999)

AM. Boon, T., "Toward a genetic analysis of tumor rejection antigens," *Adv. Cancer Res.* 58:177-210 (1992)

AN. Bretscher and Cohn, "A theory of self-nonsel discrimination," *Science* 169:1042-1049 (1970)

AO. Brodsky *et al.*, "Antigen processing and presentation," *Tissue Antigens* 47:464-471 (1996)

AP. Brunet *et al.*, "A new member of the immunoglobulin superfamily -- CTLA-4," *Nature* 328:267-270 (1987)

AQ. Carpenito *et al.*, "ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC," *Scand. J. Immunol.* 45:248-254 (1997)

AR. Chang *et al.*, "Heterogeneity in direct cytotoxic function of L3T4 T cells - TH1 clones express higher cytotoxic activity to antigen-presenting cells than TH2 clones," *J. Immunol.* 145:409-416 (1990)

AS. Chen *et al.*, "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," *Cell* 71:1093-1102 (1992)

AT. Dong *et al.*, "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," *Nat. Med.* 5:1365-1369 (1999)

AU. Dustin *et al.*, "Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3," *J. Exp. Med.* 169:503-517 (1989)

AV. Eisenlohr *et al.*, "A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes," *J. Immunol. Meth.* 154:131-138 (1992)

AW. Elliott *et al.*, "Perspectives on the role of MHC antigens in normal and malignant cell development," *Adv. Cancer Res.* 53:181-245 (1989)

AX. Fearon *et al.*, "Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response," *Cell* 60:397-403 (1990)

AY. Freeman *et al.*, "Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7," *J. Exp. Med.* 174:625-631 (1991)

AZ. Fynan *et al.*, "DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations," *Proc. Natl. Acad. Sci. USA* 90:11478-11482 (1993)

BA. Gansbacher *et al.*, "Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity," *J. Exp. Med.* 172:1217-1224 (1990)

BB. Germain, R., "The ins and outs of antigen processing and presentation," *Nature* 322:687-691 (1986)

BC. Gimmi *et al.*, "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2," *Proc. Natl. Acad. Sci. USA* 88:6575-6579 (1991)

BD. Gimmi *et al.*, "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation," *Proc. Natl. Acad. Sci. USA* 90:6586-6590 (1993)

BE. Golumbek *et al.*, "Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4," *Science* 254:713-716 (1991)

BF. Greenberg, P. D., "Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells," *Adv. Immunol.* 49:281-355 (1991)

BG. Harding *et al.*, "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," *Nature* 356:607-609 (1992)

BH. Hart *et al.*, "Priming of anti-human immunodeficiency virus (HIV) CD8⁺ cytotoxic T cells *in vivo* by carrier-free HIV synthetic peptides," *Proc. Natl. Acad. Sci. USA* 88:9448-9452 (1991)

- BI. Harty *et al.*, "CD8⁺ T cells specific for a single nonamer epitope of *Listeria monocytogenes* are protective in vivo," *J. Exp. Med.* 175:1531-1538 (1992)
- BJ. Hellström and Hellström, in *The Biologic Therapy of Cancer*, pp. 35-52, Devita *et al.*, eds., Philadelphia, J. B. Lippincott Co. (1991)
- BK. Hunt *et al.*, "Peptides presented to the immune system by the murine class II major histocompatibility complex molecule 1-A^d," *Science* 256:1817-1820 (1992)
- BL. Janeway, C.A., Jr., "Approaching the asymptote? Evolution and revolution in immunology," *Cold Spring Harbor Symp. Quant. Biol.* 54:1-13 (1989)
- BM. Jenkins *et al.*, "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells," *J. Immunol.* 140:3324-3330 (1988)
- BN. June *et al.*, "Role of the CD28 receptor in T-cell activation," *Immunol. Today* 11:211-216 (1990)
- BO. Kast *et al.*, "Protection against lethal Sendai virus infection by *in vivo* priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," *Proc. Natl. Acad. Sci. USA* 88:2283-2287 (1991)
- BP. Kotovuori *et al.*, "ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity," *J. Immunol.* 162:6613-6620 (1999)
- BQ. Koulova *et al.*, "The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4⁺ T cells," *J. Exp. Med.* 173:759-762 (1991)
- BR. Kripke, "Immunologic mechanisms in UV radiation carcinogenesis," *Adv. Cancer Res.* 34:69-75 (1981)
- BS. Lafferty *et al.*, "Immunobiology of tissue transplantation: a return to the passenger leukocyte concept," *Ann. Rev. Immunol.* 1:143-173 (1983)
- BT. LaSalle *et al.*, "Presentation of autoantigen by human T cells," *J. Immunol.* 147:774-780 (1991)
- BU. Lenschow *et al.*, "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," *Science* 257:789-792 (1992)
- BV. Ley *et al.*, "Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes *in vivo*," *Eur. J. Immunol.* 21:851-854 (1991)
- BW. Linsley *et al.*, "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1," *Proc. Natl. Acad. Sci. USA* 87:5031-5035 (1990)

- BX. Linsley *et al.*, Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," *J. Exp. Med.* 173:721-730 (1991)
- BY. Liu *et al.*, "Heat-stable antigen is a costimulatory molecule for CD4 T cell growth," *J. Exp. Med.* 175:437-445 (1992)
- BZ. McKisic *et al.*, "Cytolytic activity of murine CD4⁺ T cell clones correlates with IFN- γ production in mouse strains having a BALB/c background," *J. Immunol.* 150:3793-3805 (1993)
- CA. Melief, C. J. M., "Tumor eradication of adoptive transfer of cytotoxic T lymphocytes," *Adv. Cancer Res.* 58:143-175 (1992)
- CB. Mueller *et al.*, "Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy," *Ann. Rev. Immunol.* 7:445-480 (1989)
- CC. Nabel *et al.*, "Site-specific gene expression in vivo by direct gene transfer into the arterial wall," *Science* 249:1285-1288 (1990)
- CD. Nossal, G. J. V., "Immunologic tolerance: collaboration between antigen and lymphokines," *Science* 245:147-153 (1989)
- CE. Ostrand-Rosenberg *et al.*, "Rejection of mouse sarcoma cells after transfection of MHC class II genes," *J. Immunol.* 144:4068-4071 (1990)
- CF. Ozdemirli *et al.*, "The cytotoxic process of CD4 Th1 clones," *J. Immunol.* 149:1889-1895 (1992)
- CG. Parra *et al.*, "The role of B7-1 and LFA-3 in costimulation of CD8⁺ T cells," *J. Immunol.* 158:637-642 (1997)
- CH. Reiser *et al.*, "Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex," *Proc. Natl. Acad. Sci. USA* 89:271-275 (1992)
- CI. Rock *et al.*, "Analysis of the association of peptides of optimal length to class I molecules on the surface of cells," *Proc. Natl. Acad. Sci. USA* 89:8918-8922 (1992)
- CJ. Rosenberg *et al.*, "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes," *Science* 233:1318-1321 (1986)
- CK. Rosenberg *et al.*, "Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes," *Ann. Rev. Immunol.* 4:681-709 (1986)
- CL. Rötzschke *et al.*, "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," *Nature* 348:252-254 (1990)

- CM. Rudensky *et al.*, "Sequence analysis of peptides bound to MHC class II molecules," *Nature* 353:622-627 (1991)
- CN. Salomon *et al.*, "Cutting edge: LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production," *J. Immunol.* 161:5138-5142 (1998)
- CO. Schreiber *et al.*, "Unique tumor-specific antigens," *Ann. Rev. Immunol.* 6:465-483 (1988)
- CP. Schulz *et al.*, "Peptide-induced antiviral protection by cytotoxic T cells," *Proc. Natl. Acad. Sci. USA* 88:991-993 (1991)
- CQ. Schwartz, "Acquisition of immunologic self-tolerance," *Cell* 57:1073-1081 (1989)
- CR. Selvakumar *et al.*, "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," *Immunogenetics* 36:175-181 (1992)
- CS. Staunton *et al.*, "Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families," *Cell* 52:925-933 (1988)
- CT. Swallow *et al.*, "B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF α ," *Immunity* 11:423-432 (1999)
- CU. Thompson *et al.*, "CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines," *Proc. Natl. Acad. Sci. USA* 86:1333-1337 (1989)
- CV. Townsend *et al.*, "Antigen recognition by class I-restricted T lymphocytes," *Ann. Rev. Immunol.* 7:601-624 (1989)
- CW. Townsend *et al.*, "Tumor rejection after direct costimulation of CD8⁺ T cells by B7-transfected melanoma cells," *Science* 259:368-370 (1993)
- CX. Turka *et al.*, "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection *in vivo*," *Proc. Natl. Acad. Sci. USA* 89:11102-11105 (1992)
- CY. van-Seventer *et al.*, "The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells," *J. Immunol.* 144:4579-4586 (1990)
- CZ. Wallner *et al.*, "Primary structure of lymphocyte function-associated antigen 3 (LFA-3) - The ligand of the T lymphocyte CD2 glycoprotein," *J. Exp. Med.* 166:923-932 (1987)

DA. Wingren *et al.*, "T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles," *Crit. Rev. Immunol.* 15:235-253 (1995)

DB. Wolff *et al.*, "Direct gene transfer into mouse muscle in vivo," *Science* 247:1465-1468 (1990)

DC. Young *et al.*, "The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4⁺ T lymphocytes by human blood dendritic cells in vitro," *J. Clin. Invest.* 90:229-237 (1992)

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants believe that their invention as claimed is patentable over the above references taken alone or in any combination. However, Applicants reserve the right to demonstrate that their claimed invention was made prior to any one or more of the above-identified references. No inference should be drawn as to the pertinence of the references based on the order in which they are presented.

Applicants respectfully request that the Examiner review the foregoing references to make her own determination of the patentability of the present invention and that the references be made of record in the file of this application.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action and after three months of the filing date, but prior to the Notice of Allowance or Final Office Action.

CERTIFICATION

I hereby certify that no item of information in the information disclosure statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of this information disclosure statement.

Although no fee is believed to be due, the Commissioner is hereby authorized to charge any fees necessitated by this transmittal to Townsend and Townsend Deposit Account No. 20-1430.

Respectfully submitted,

Dated: 31 January 2003

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111
Tel.: (206) 467-9600
Fax: (415) 576-0300




BEST AVAILABLE COPY

FORM PTO-1449 (Modified)				Attorney Docket No.: 015280-415100US		Application No.: 09/810,310	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Samir Khleif <i>et al.</i>			
				Filing Date: March 14, 2001		Group: 1644	
Reference Designation				U.S. PATENT DOCUMENTS		Page 1 of 1	
Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
	AA.	4,599,230	July 8, 1986	Milich <i>et al.</i>			
	AB.	4,599,231	July 8, 1986	Milich <i>et al.</i>			
	AC.	5,861,310	Jan. 19, 1999	Freeman <i>et al.</i>			
	AD.	5,866,553	Feb. 2, 1999	Donnelly <i>et al.</i>			
	AE.	5,942,607	Aug. 24, 1999	Freeman <i>et al.</i>			
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
	AF.	90/11092	Oct. 4, 1990	WO			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AG.	Acsadi <i>et al.</i> , "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," <i>Nature</i> 352:815-818 (1991)					
	AH.	Aichele <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> 171:1815-1820 (1990)					
	AI.	Armitage <i>et al.</i> , "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> 357:80-82 (1992)					
	AJ.	Azuma <i>et al.</i> , "B70 antigen is a second ligand for CTLA-4 and CD28," <i>Nature</i> 366:76-79 (1993)					
	AK.	Baskar <i>et al.</i> , "Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:5687-5690 (1993)					
	AL.	Bleijs <i>et al.</i> , "Co-stimulation of T cells results in distinct IL-10 and TNF- α cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3," <i>Eur. J. Immunol.</i> 29:2248-2258 (1999)					
	AM.	Boon, T., "Toward a genetic analysis of tumor rejection antigens," <i>Adv. Cancer Res.</i> 58:177-210 (1992)					
	AN.	Bretscher and Cohn, "A theory of self-nonsel discrimination," <i>Science</i> 169:1042-1049 (1970)					
	AO.	Brodsky <i>et al.</i> , "Antigen processing and presentation," <i>Tissue Antigens</i> 47:464-471 (1996)					
	AP.	Brunet <i>et al.</i> , "A new member of the immunoglobulin superfamily -- CTLA-4," <i>Nature</i> 328:267-270 (1987)					
	AQ.	Carpenito <i>et al.</i> , "ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC," <i>Scand. J. Immunol.</i> 45:248-254 (1997)					
	AR.	Chang <i>et al.</i> , "Heterogeneity in direct cytotoxic function of L3T4 T cells - TH1 clones express higher cytotoxic activity to antigen-presenting cells than TH2 clones," <i>J. Immunol.</i> 145:409-416 (1990)					
	AS.	Chen <i>et al.</i> , "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," <i>Cell</i> 71:1093-1102 (1992)					
	AT.	Dong <i>et al.</i> , "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," <i>Nat. Med.</i> 5:1365-1369 (1999)					

FORM PTO-1449 (Modified)		Attorney Docket No.: 015280-415100US	Application No.: 09/810,310
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Samir Khleif <i>et al.</i>	
		Filing Date: March 14, 2001	Group: 1644

	AU.	Dustin <i>et al.</i> , "Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3," <i>J. Exp. Med.</i> 169:503-517 (1989)
		Eisenlohr <i>et al.</i> , "A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes," <i>J. Immunol. Meth.</i> 154:131-138 (1992)
		Elliott <i>et al.</i> , "Perspectives on the role of MHC antigens in normal and malignant cell development," <i>Adv. Cancer Res.</i> 53:181-245 (1989)
	AX.	Fearon <i>et al.</i> , "Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response," <i>Cell</i> 60:397-403 (1990)
	AY.	Freeman <i>et al.</i> , "Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7," <i>J. Exp. Med.</i> 174:625-631 (1991)
	AZ.	Fynan <i>et al.</i> , "DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations," <i>Proc. Natl. Acad. Sci. USA</i> 90:11478-11482 (1993)
	BA.	Gansbacher <i>et al.</i> , "Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity," <i>J. Exp. Med.</i> 172:1217-1224 (1990)
	BB.	Germain, R., "The ins and outs of antigen processing and presentation," <i>Nature</i> 322:687-691 (1986)
	BC.	Gimmi <i>et al.</i> , "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2," <i>Proc. Natl. Acad. Sci. USA</i> 88:6575-6579 (1991)
	BD.	Gimmi <i>et al.</i> , "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation," <i>Proc. Natl. Acad. Sci. USA</i> 90:6586-6590 (1993)
	BE.	Golumbek <i>et al.</i> , "Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4," <i>Science</i> 254:713-716 (1991)
	BF.	Greenberg, P. D., "Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells," <i>Adv. Immunol.</i> 49:281-355 (1991)
	BG.	Harding <i>et al.</i> , "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> 356:607-609 (1992)
	BH.	Hart <i>et al.</i> , "Priming of anti-human immunodeficiency virus (HIV) CD8 ⁺ cytotoxic T cells <i>in vivo</i> by carrier-free HIV synthetic peptides," <i>Proc. Natl. Acad. Sci. USA</i> 88:9448-9452 (1991)
	BI.	Harty <i>et al.</i> , "CD8 ⁺ T cells specific for a single nonamer epitope of <i>Listeria monocytogenes</i> are protective <i>in vivo</i> ," <i>J. Exp. Med.</i> 175:1531-1538 (1992)
	BJ.	Hellström and Hellström, in <i>The Biologic Therapy of Cancer</i> , pp. 35-52, Devita <i>et al.</i> , eds., Philadelphia, J. B. Lippincott Co. (1991)
	BK.	Hunt <i>et al.</i> , "Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A ^d ," <i>Science</i> 256:1817-1820 (1992)
	BL.	Janeway, C.A., Jr., "Approaching the asymptote? Evolution and revolution in immunology," <i>Cold Spring Harbor Symp. Quant. Biol.</i> 54:1-13 (1989)
	BM.	Jenkins <i>et al.</i> , "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells," <i>J. Immunol.</i> 140:3324-3330 (1988)
	BN.	June <i>et al.</i> , "Role of the CD28 receptor in T-cell activation," <i>Immunol. Today</i> 11:211-216 (1990)
	BO.	Kast <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287 (1991)
	BP.	Kotovuori <i>et al.</i> , "ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity," <i>J. Immunol.</i> 162:6613-6620 (1999)
	BQ.	Koulova <i>et al.</i> , "The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4 ⁺ T cells," <i>J. Exp. Med.</i> 173:759-762 (1991)
	BR.	Kripke, "Immunologic mechanisms in UV radiation carcinogenesis," <i>Adv. Cancer Res.</i> 34:69-75 (1981)
	BS.	Lafferty <i>et al.</i> , "Immunobiology of tissue transplantation: a return to the passenger leukocyte concept," <i>Ann. Rev. Immunol.</i> 1:143-173 (1983)

FORM PTO-1449 (Modified)		Attorney Docket No.: 015280-415100US	Application No.: 09/810,310
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Samir Khleif <i>et al.</i>	
		Filing Date: March 14, 2001	Group: 1644

	BT.	LaSalle <i>et al.</i> , "Presentation of autoantigen by human T cells," <i>J. Immunol.</i> 147:774-780 (1991)
	BQ.	Lenschow <i>et al.</i> , "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," <i>Science</i> 257:789-792 (1992)
	BR.	Ley <i>et al.</i> , "Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes <i>in vivo</i> ," <i>Eur. J. Immunol.</i> 21:851-854 (1991)
	BW.	Linsley <i>et al.</i> , "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1," <i>Proc. Natl. Acad. Sci. USA</i> 87:5031-5035 (1990)
	BX.	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," <i>J. Exp. Med.</i> 173:721-730 (1991)
	BY.	Liu <i>et al.</i> , "Heat-stable antigen is a costimulatory molecule for CD4 T cell growth," <i>J. Exp. Med.</i> 175:437-445 (1992)
	BZ.	McKisic <i>et al.</i> , "Cytolytic activity of murine CD4 ⁺ T cell clones correlates with IFN- γ production in mouse strains having a BALB/c background," <i>J. Immunol.</i> 150:3793-3805 (1993)
	CA.	Melief, C. J. M., "Tumor eradication of adoptive transfer of cytotoxic T lymphocytes," <i>Adv. Cancer Res.</i> 58:143-175 (1992)
	CB.	Mueller <i>et al.</i> , "Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy," <i>Ann. Rev. Immunol.</i> 7:445-480 (1989)
	CC.	Nabel <i>et al.</i> , "Site-specific gene expression <i>in vivo</i> by direct gene transfer into the arterial wall," <i>Science</i> 249:1285-1288 (1990)
	CD.	Nossal, G. J. V., "Immunologic tolerance: collaboration between antigen and lymphokines," <i>Science</i> 245:147-153 (1989)
	CE.	Ostrand-Rosenberg <i>et al.</i> , "Rejection of mouse sarcoma cells after transfection of MHC class II genes," <i>J. Immunol.</i> 144:4068-4071 (1990)
	CF.	Ozdemirli <i>et al.</i> , "The cytotoxic process of CD4 Th1 clones," <i>J. Immunol.</i> 149:1889-1895 (1992)
	CG.	Parra <i>et al.</i> , "The role of B7-1 and LFA-3 in costimulation of CD8 ⁺ T cells," <i>J. Immunol.</i> 158:637-642 (1997)
	CH.	Reiser <i>et al.</i> , "Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex," <i>Proc. Natl. Acad. Sci. USA</i> 89:271-275 (1992)
	CI.	Rock <i>et al.</i> , "Analysis of the association of peptides of optimal length to class I molecules on the surface of cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:8918-8922 (1992)
	CJ.	Rosenberg <i>et al.</i> , "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes," <i>Science</i> 233:1318-1321 (1986)
	CK.	Rosenberg <i>et al.</i> , "Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes," <i>Ann. Rev. Immunol.</i> 4:681-709 (1986)
	CL.	Rötzschke <i>et al.</i> , "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254 (1990)
	CM.	Rudensky <i>et al.</i> , "Sequence analysis of peptides bound to MHC class II molecules," <i>Nature</i> 353:622-627 (1991)
CN.	Salomon <i>et al.</i> , "Cutting edge: LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production," <i>J. Immunol.</i> 161:5138-5142 (1998)	
CO.	Schreiber <i>et al.</i> , "Unique tumor-specific antigens," <i>Ann. Rev. Immunol.</i> 6:465-483 (1988)	
CP.	Schulz <i>et al.</i> , "Peptide-induced antiviral protection by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. USA</i> 88:991-993 (1991)	
CQ.	Schwartz, "Acquisition of immunologic self-tolerance," <i>Cell</i> 57:1073-1081 (1989)	
CR.	Selvakumar <i>et al.</i> , "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," <i>Immunogenetics</i> 36:175-181 (1992)	
CS.	Staunton <i>et al.</i> , "Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families," <i>Cell</i> 52:925-933 (1988)	
CT.	Swallow <i>et al.</i> , "B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF α ," <i>Immunity</i> 11:423-432 (1999)	

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.